Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYTĀ® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
Filing Date
Aug 17, 2022
Document Date
Aug 17, 2022
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp